November 16, 2018 / 9:46 PM / a month ago

BRIEF-FDA Approves Novartis Drug Promacta For First-Line SAA

Nov 16 (Reuters) - Novartis AG:

* FDA APPROVES NOVARTIS DRUG PROMACTA FOR FIRST-LINE SAA AND GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR ADDITIONAL NEW INDICATION

* NOVARTIS AG - DECISION ON PROMACTA BY EUROPEAN MEDICINES AGENCY IS EXPECTED IN 2019

* NOVARTIS AG - PROMACTA RECEIVES FDA APPROVAL FOR FIRST-LINE TREATMENT OF SEVERE APLASTIC ANEMIA

* NOVARTIS AG - PROMACTA RECEIVES FDA APPROVAL FOR BREAKTHROUGH THERAPY DESIGNATION FOR LOW PLATELET COUNTS IN PEOPLE EXPOSED TO RADIATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below